8p11.2 deletion syndrome

8p11.2 deletion syndrome (also known as chromosome 8p11.2 deletion syndrome) is a rare chromosomal disorder caused by a microdeletion on the short arm of chromosome 8 at band 11.2. This region contains several genes, including FGFR1 (fibroblast growth factor receptor 1), which plays a critical role in development. The deletion typically arises de novo, meaning it occurs as a new genetic event rather than being inherited from a parent. The syndrome affects multiple body systems and is characterized by developmental delay, intellectual disability, and distinctive facial features. Affected individuals may present with speech and language delays, behavioral difficulties, and variable degrees of cognitive impairment. Craniofacial features can include a prominent forehead, hypertelorism (widely spaced eyes), and a broad nasal bridge. Some patients may also exhibit hypogonadotropic hypogonadism due to loss of FGFR1, which is associated with Kallmann syndrome when disrupted. Growth abnormalities, skeletal anomalies, and congenital heart defects have also been reported in some cases. There is currently no cure or specific targeted therapy for 8p11.2 deletion syndrome. Management is supportive and symptom-based, involving early intervention programs, speech therapy, occupational therapy, and special educational support. Hormonal replacement therapy may be necessary for individuals with hypogonadism. Regular monitoring by a multidisciplinary team including geneticists, endocrinologists, cardiologists, and developmental specialists is recommended to address the variable clinical manifestations of this condition.

Common questions about 8p11.2 deletion syndrome